Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy

Cancer Research

Volumn 58, Issue 11, 1998, Pages 2282-2287

  Segawa, Takehiko ^a,b   Takebayashi, Hirohide ^a,b   Kakehi, Yoshiyuki ^b   Yoshida, Osamu ^b   Narumiya, Shuh ^b   Kakizuka, Akira ^a  

^a OSAKA BIOSCIENCE INSTITUTE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; POLYGLUTAMINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DEATH; GENE AMPLIFICATION; GENE EXPRESSION; GENE REPLICATION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; TRANSGENE;

APOPTOSIS; FUNGAL PROTEINS; GENE AMPLIFICATION; GENE THERAPY; HELA CELLS; HUMANS; MALE; PEPTIDES; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0032101616     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. Hrouda, D., and Dalgleish, A. G. Gene therapy for prostate cancer. Gene Ther., 3: 845-852, 1996.
3. McCormack, R. T., Rittenhouse, H. G., Finlay, J. A., Sokoloff, R. L., Wang, T. J., Wolfert, R. L., Lilja, H., and Oesterling, J. E. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology, 45: 729-744, 1995.
4. Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., and Henderson, D. R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem., 271: 7043-7051, 1996.
5. Cleutjens, K. B., van Eekelen, C. C., van der Korput, H. A., Brinkman, A. O., and Trapman, J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem., 271: 6379-6388, 1996.
6. Wei, C., Willis, R. A., Tilton, B. R., Looney, R. J., Lord, E. M., Barth, R. K., and Frelinger, J. G. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc. Natl. Acad. Sci. USA, 94: 6369-6374, 1997.
7. Cleutjens, K. B., van der Korpul, H. A., Ehren van Eekelen, C. C., Sikes, R. A., Fasciana, C., Chung, L. W., and Trapman, J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol. Endocrinol., 11: 1256-1265, 1997.
8. Roth, J. A., and Cristiano, R. J. Gene therapy tor cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89: 21-39, 1997.
9. Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S., and Kakizuka, A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet., 13: 196-202, 1996.
10. Pang, S., Dannull, J., Kaboo, R., Xie, Y., Tso, C. L., Michel, K., deKemion, J. B., and Belldegrun, A. S. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res., 57: 495-199, 1997.
11. deWet, J. R., Wood, K. V., DeLuca, M., Helinski, D. R., and Suhramani, S. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol., 7: 725-737, 1987.
12. Kang, T., Martins, T., and Sadowski, I. Wild type GAL4 hinds cooperatively to the GAL1-10 UASG in vitro. J. Biol. Chem., 268: 9629-9635, 1993.
13. Lee, C. H., Liu, M., Sie, K. L., and Lee, M. S. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase α and topoisomerase II α in prostate cancer. Anticancer Res., 16: 1805-1811, 1996.
14. Sadowski, L, Ma, J., Triezenberg, S., and Ptashne, M. GAL4-VP16 is an unusually potent transcriptional activator. Nature (Lond.), 335: 563-564, 1988.
15. Kawaguchi, Y., Takebayashi, H., Kakizuka, A., Arii, S., Kato, M., and Imamura, M. Expression of Fas-estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines. Cancer Lett., 116: 53-59, 1997.
16. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
17. Miller, N., and Whelan, J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum. Gene Ther., 8: 803-815, 1997.
18. Kanegae, Y., Lee, G., Sato, Y., Tanaka, M., Nakai, M., Sakai, T., Sugano, S., and Saito, I. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res., 23: 3816-3821, 1995.
19. Takebayashi, H., Oida, H., Fujisawa, K., Yamaguchi, M., Hikida, T., Fukumoto, M., Narumiya, S., and Kakizuka, A. Hormone-induced apoptosis hy Fas-nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo. Cancer Res., 56: 4164-4170, 1996.
20. Kakizuka, A. Degenerative ataxias: genetics, pathogenesis and animal models. Curr. Opin. Neuro., 10: 285-290, 1997.